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This article  describes  the  methodological  challenges  associated  with  disease-based  inter-
national comparison  of health  system  performance  and  how  they have  been  addressed  in
the EuroHOPE  (European  Health  Care  Outcomes,  Performance  and  Efﬁciency)  project.  The
project  uses  linkable  patient-level  data  available  from  national  sources  of  Finland,  Hungary,
Italy,  The  Netherlands,  Norway,  Scotland  and  Sweden.  The  data  allow  measuring  the  out-
come and  the  use  of  resources  in  uniformly-deﬁned  patient  groups  using  standardized
risk  adjustment  procedures  in  the  participating  countries.  The  project  concentrates  on  ﬁve
important  disease  groups:  acute  myocardial  infarction  (AMI),  ischemic  stroke,  hip  fracture,
breast  cancer  and  very  low  birth  weight  and  preterm  infants  (VLBWI).  The  essentials  of data
gathering,  the  deﬁnition  of  the episode  of  care,  the  developed  indicators  concerning  base-
line statistics,  treatment  process,  cost  and  outcomes  are  described.  The  preliminary  results
indicate  that  the  disease-based  approach  is  attractive  for international  performance  analy-
ses,  because  it produces  various  measures  not  only  at country  level  but  also  at regional  and
hospital level  across  countries.  The  possibility  of  linking  hospital  discharge  register  to  other
databases  and  the  availability  of  comprehensive  register  data  will  determine  whether  the
approach can be  expanded  to  other  diseases  and  countries.
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1. Introduction
International comparison of performance can proceed
at a number of possible levels, including system wide,
by disease, and by sub-sector (such as hospital or nurs-
ing homes) [1]. There are arguments for and against each,
but when it comes to health outcomes the disease-based
Open access under CC BY-NC-SA license.approach is the most suitable, since the health gains of the
activities can be measured quite accurately at the disease
level [2]. Compared with system wide comparison, this
approach reduces heterogeneity of the population studied
er CC BY-NC-SA license.
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Table 1
EuroHOPE in a nutshell.
Project name European Health Care Outcomes, Performance and Efﬁciency (EuroHOPE).
Main task To contemplate and compare national as well as international differences in ﬁve economically important patient
groups with respect to effectiveness and efﬁciency of their whole cycle of care.
Patient groups Acute myocardial infarction, stroke, hip fracture, breast cancer, and very low birth weight and very preterm infants.
Coordinator National Institute for Health and Welfare, Finland.
Partners Karolinska Institutet, Sweden; Ragnar Frisch Centre for Economic Research, Norway; University of Oslo, Norway;
 Univers
alth and
project. The project is based on merged register data.University of Edinburgh, UK (Scotland);
Hungary; National Institute of Public He
Duration 4 years, 2010–2013.
and allows more precise identiﬁcation of the characteristics
of the health care process that have an effect on
outcomes.
All international comparisons require suitable infor-
mation systems. These systems have until now been
developed using two different approaches. The ﬁrst
approach relies on developing a coherent conceptual
framework for information collection, analysis and dis-
semination. An example of this is national accounts, in
which health care is dealt as a part of the whole economy.
Another approach assembles readily accessible data, often
the by-products of existing national data collection, such as
hospital discharge registers, as well as work that has been
done for other purposes. The bottom-up approach relies on
individual experts, provider organizations, and countries
engaging in quality and efﬁciency improvement initiatives.
Micro-level comparative data on clinical actions, costs
and outcomes represents an essential element of such an
approach. In this case, the precise deﬁnition, collection and
scrutiny of the data are left to expert groups to determine
[3].
A desirable health care performance measure at the dis-
ease level is one that reliably and accurately reﬂects the
process, costs and outcome of care [4]. Such a measure
provides valuable information for improving treatment
processes and for steering at national, regional as well as
hospital levels. In addition, measures that enable reliable
comparisons across providers might encourage them to
develop their treatment processes to attain better position-
ing in benchmarking.
By making use of available databases through a microe-
conomic disease-based approach,2 the EuroHOPE project
(European Health Care Outcomes, Performance and Efﬁ-
ciency, Table 1) evaluates the performance of European
health care systems in terms of outcomes, quality, use of
resources and cost. EuroHOPE uses patient-level data avail-
able from linkable national or regional registers and other
data sources that allow for measuring the outcome (by fol-
lowing what happens to patients) and the use of resources
(such as cost, number of hospital days, treatment with spe-
ciﬁc procedures and drugs) in the selected well-deﬁned and
risk adjusted patient groups.3 Thus, EuroHOPE is not only
2 The EuroHOPE project applies sub-sector approach to Nordic hospi-
tals. This will be discussed elsewhere in this issue [29].
3 This idea is not novel, however. For example, Eurostat [30] has deﬁned
the output in health care: “Health output is the quantity of care received by
patients, adjusted to allow for the qualities of service provided, for each
type of health care. The quantities should be weighted together using
data on the costs or prices of the health care provided. The quantity ofita Commerciale Luigi Bocconi, Italy; Semmelweis University,
 Environment, Netherlands.
focusing on a speciﬁc treatment or hospital stay (measured
e.g. in term of DRGs) [5] per se, but rather on outcomes and
costs related to the complete clinical pathway.
Using register data it is not possible to consider patient
or provider experiences. For example, no information on
health-related quality of life nor patient satisfaction is rou-
tinely available in the registers and thus cannot be used
for enriching comparisons between regions or hospitals. In
order to ﬁll the gap, feasibility studies making use of patient
surveys on health-related quality of life and patient sat-
isfaction in selected hospitals in each country have been
initiated in EuroHOPE.4
The project concentrates on ﬁve disease groups: acute
myocardial infarction (AMI), ischemic stroke, hip fracture,
breast cancer and very low birth weight and preterm
infants (VLBWI). The approach is based on analysing the
progress of a disease, with speciﬁc interest in the role of
health services and health care policy as a determinant
of the progress. The main idea of the approach is that it
analyses performance by using detailed data pertaining to
speciﬁc health conditions to illuminate the interconnected
aspects (i.e. ﬁnancing, organizational structures, medical
technology choices) that are responsible for health system
performance (i.e. health outcomes and expenditure). Of the
seven countries participating in EuroHOPE, ﬁve countries
are considered as tax-based systems and two countries
rely on social health insurance. Two  of the tax-based sys-
tems, Norway and Scotland, mainly rely on central taxation,
whereas the other three, Finland, Italy and Sweden, in
various ways rely on regional and local taxes. The two
countries with social insurance systems also differ as The
Netherlands rely on a system with multiple insurers and
regulated competition among them, whereas the Hungar-
ian system is a social health insurance system with a sole
insurer with a monopsony power.
This article describes the methodological challenges
of international comparisons related to a disease-based
approach and how they are addressed in the EuroHOPEThus, this article shows how existing data sources can be
health care received by patients should be measured in terms of complete
treatments.¨
4 Feasibility will be studied in two  different dimensions: in establishing
common protocols for survey data collection in differing countries, and
in  collecting information in differing patient groups. For health related
quality of life two different measures EQ-5D and 15D and for patient sat-
isfaction EORTC-IN-PATSAT32 have been utilised together with collection
of  rich background information.
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and from the necessary variables concerning the care given,
(iv) checking history and follow-up of the use of health care
services in order to deﬁne state and time variables for theFig. 1. Eur
xploited in performance analysis using the bottom-up
pproach.
. Methodology and data
A performance measure must be carefully constructed
nd be appropriate for comparisons in order to be useful.
here are many important and well-documented method-
logical and practical questions that need to be considered
hen administrative data are used for performance mea-
urement [6–9]. Performance indicators will vary due to
ype of hospital, regional or individual level variations or
andom variation. The focus of our interest is in varia-
ion at the hospital, regional level and country level. In
uroHOPE, cross-country heterogeneity (e.g. in comorbid-
ty conditions) is reduced by using proper risk adjustment
ethods for individual-level data.
Implementing register-based performance evaluation
equires – in addition to the availability of comprehensive
ata – methodological understanding and a multidisci-
linary involvement. Health system knowledge is essential
or deciding the scope and the speciﬁc questions to be
ddressed, and needs to be supplemented with under-
tanding of the possibilities and limitations of register
nformation [10]. Clinical knowledge is needed when
ppraising details of the indication and management of a
isease, and economic, epidemiological, statistical and data
ining expertise are required to ensure that the method-
logy is appropriate. Finally, all the aforementioned must
e integrated during the entire process. In EuroHOPE, the
erformance indicators have been developed in collabo-
ation with clinical experts for all the diseases in focus as
ell as with experts in health economics, epidemiology and
tatistics.
The ﬁve EuroHOPE disease groups were chosen because
hey have high prevalence, health impact or high economic
urden in all developed countries (AMI, ischemic stroke,
ip fracture, breast cancer [11]), or they are very resource
ntense (VLBWI). Different populations are in focus, such
s the elderly (AMI, ischemic stroke, hip fracture), middle
ged (breast cancer) and newborn (VLBWI) or the risk foratabases.
the conditions differ by sex (AMI, hip fracture and breast
cancer). The diseases differ in the involvement of different
types of specialities, regarding either surgical treatment
or outpatient pharmaceutical treatment, and also with
respect to technological change. As a result, the impact
of health system characteristics (ﬁnancing, organization,
technology, etc.) can be tested across a diverse set of areas,
creating a stronger, more comprehensive evidence base.
The choice is also based on a pre-enquiry and the assump-
tion that these diseases offer the best possibilities to access
internationally comparative data, since in all of the diseases
the main responsibility for patient treatment falls to acute
hospital care.
We  developed an international comparative database
that allows performance analysis, research and use indi-
cators calculated at national, regional and hospital levels
(Fig. 1). The disease-based approach requires patient-level
data covering the whole population and the possibility
to deterministically link records in different national reg-
isters. In the six included countries (Finland, Hungary,
the Netherlands,5 Norway, Sweden and Scotland) included
in the EuroHOPE project it was possible to link national
hospital-discharge registers with mortality registers and
in ﬁve countries (excluding Scotland) also with registers of
prescribed medicines (Table 2). In Italy, similar data were
available for two  geographical areas. All databases present
population data reﬂecting patterns of care and outcomes
of the entire population residing in the deﬁned territories.
For each disease, the building of the database is based
on several stages: (i) deﬁnition of the patient population,
(ii) collection of the register material for the patient pop-
ulation at hand, (iii) deﬁnition of the start and end of the
episode (by deﬁning and using the index admission and
deciding how referrals should be treated) for the patients5 In the Netherlands the data is available of about 85% of the patients,
since collection of national discharge data is voluntary.
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Table 2
Registers used in EuroHOPE.
Country Register name (year since included in EuroHOPE) Sub-studies in which
the register is used
Finland Hospital discharge register 1–5
Cause of death register 1–5
Drug  prescription register 1–5
Cancer register 4
Medical birth register 5
Data  ﬁle on small preterm infants 5
Register of congenital malformations 5
Hungary Hospital discharge register 1–5
Death register 1–5
Prescribed medicine register 1–5
Cancer register 4
Child  birth register 5
Italy Hospital discharge register 1–5
Causes of death register 1–5
Register of medicine prescribed and dispensed by the Italian NHS 1–5
Outpatient services in specialist care register 1–5
Cancer register (only city of Turin) 4
Medical birth registry (only province of Rome) 5
The
Netherlands
Hospital discharge register 1–3,5
Causes of death register 1–3,5
Prescribed drug register 1–3,5
The  Netherlands perinatal registry 5
Norway Norwegian patient register 1, 3–5
Norwegian prescription database 1, 3–5
National cancer register 4
Cause of death register 1, 3–5
Medical birth registry of Norway 5
The  Norwegian hip fracture register 3
Scotland Scottish morbidity record 00 – outpatient attendance 1–5
Scottish morbidity record 01 – general acute inpatient and day case 1–5
National records of Scotland death extract 1–5
Scottish open cancer registration and tumor enumeration system 4
National records of Scotland birth extract 5
Scottish birth record 5
Scottish morbidity record 02 – maternity inpatient and day case 5
Sweden National patient register 1–5
National cause of death register 1–5
National prescribed drug register 1–5
National cancer register 4
rth weigNational medical birth register 
Sub-studies: 1 AMI, 2 stroke, 3 hip fracture, 4 breast cancer, 5 very low bi
patients, (v) construction of the comorbidity variables, (vi)
calculation of the direct health care cost, and ﬁnally, (vii)
combination of the information of the previous stages in
order to generate the comparison database.
3. The development of performance measurement
3.1. Episode of care
The concept of an episode has been used to distinguish
between discharge and single intervention. The idea of an
episode approach is not new [12,13], but the implementa-
tion of this concept has been challenging in practice [14]
and has not been done before in such a large scale.An episode of care refers to the entire treatment pattern
from the beginning of the disease (e.g. time of diagnosis)
to the end of the treatment across organizational bound-
aries to face the health problem at hand in a speciﬁc time5
ht and very preterm infants.
frame. Thus the protocol for an episode includes the deﬁni-
tions of starting and ﬁnishing dates (follow-up time) as well
as inclusion and exclusion criteria, which are used when
constructing a comparison data set for a speciﬁc disease
group.
In EuroHOPE, the follow-up data covers at least one year
for each patient. Main observable events in register data
are process measures such as admissions, procedures, and
discharges as well as outcomes measures such as survival.
Secondary observable events are outpatient visits and pre-
scribed medication purchases. In addition to the follow-up
data, we have similar information on the history of service
use of the patients. Using the available data it is possible
to reconstruct treatment pathways that describe what has
happened (before and) after e.g. an operation on a daily
basis [10] (Fig. 2).
Episode of care provides a framework that can be opera-
tionalized in terms of linkable register data. In order to
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odel the episode of care and calculate the measures of
erformance, the nature of the disease and the medical
istory and comorbidities of the patients must be taken
nto account, all key factors affecting treatment decisions,
elivery of care, and outcomes.
The episodes for AMI, ischemic stroke, and hip fracture
tart with an acute phase in the hospital, usually occur-
ing immediately after the event. In the case of VLBWI and
reast cancer the episode starts with birth or a disease
vent, respectively, followed by hospital use. The hospi-
al admission that is the ﬁrst in the episode of care is in
ur terminology deﬁned as the index admission, and the
dmission day the index day. The ﬁrst hospital episode
tarts on the index day and terminates at the day of the ﬁrst
ischarge to home, or by death, or after a speciﬁed time of
ontinuous inpatient care, depending on the disease. The
rst hospital episode describes the acute-phase of treat-
ent. The follow-up period ends one year after the index
ay or at death. The total episode of care includes all the
ealth service used during the follow-up period (Fig. 2). For
MI, ischemic stroke and hip fracture patients, the index
ay (i.e. the beginning of episode) is deﬁned by means of the
ain diagnosis of the hospital stay (AMI ICD-10-codes I21-
122, ischemic stroke I63, hip fracture S72.0-S72.2) using at
east two exclusions. First, we exclude all patients who have
ad a hospital admission related the disease in question
uring the previous 365 days before the index day. Second,
e exclude non-residents and patients with an incomplete
ersonal identity number (PID).
.2. Indicators
The benchmarking task of the project is carried out
hrough basic reports (available on the internet) which
nclude performance indicators at national and regional
evel. The indicators presented in the disease-speciﬁc basic
eports can be roughly categorized into four differentation in EuroHOPE.
groups: baseline statistics, process indicators, cost indica-
tors, and outcome indicators.
In each disease-speciﬁc analysis, the baseline statistics
of the patient population in each country and region are
given. These include, e.g. the number of patients affected
by the disease, mean and median age and proportion of
males and females.
3.2.1. Process
The process indicators describe health care service use
during the episode of care. The indicators include meas-
ures such as length of stay in hospitals (in ﬁrst hospital
episode and during the follow-up period), procedures and
other treatment practices, and use of prescribed medicines.
3.2.2. Costs
The cost indicators describe the cost of ﬁrst hospi-
tal episode and the total episode of care. Ideally, there
would be detailed cost calculations for each individual
patient available and standardized method of cost calcu-
lations across countries. Although many of the countries
are using Diagnostic Related Groups (DRGs) or a similar
system to calculate resource use related to standardized
patients, there is no common method of grouping patients
[15] and DRG tariffs may  not accurately reﬂect costs. Since
Geue et al. [16] show that the costing method may have
an important impact on how the effects of explanatory
variables on cost are assessed, it is important to ﬁnd meas-
ures that are considered to be valid and comparable. As a
prerequisite each country should be capable of providing
the necessary data input. In EuroHOPE, the cost and uti-
lization measures are in general limited to hospital care
(inpatient and outpatient) and pharmaceuticals dispensed
outside hospital.Two approaches that are designed to complement each
other are set up. In the ﬁrst approach, the essential com-
ponents of resource use during the hospital treatment are
deﬁned and extracted from register data at the individual
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Table 3
Description of regions used in EuroHOPE reporting.
Country Description Number of regions Average population size
Finland Hospital districts and hospital regions responsible for
providing specialized health care. Smallest districts
combined.
19 280,000
Hungary 19 counties and Budapest area providing
self-governmental administrative duties (not health care).
20 500,000
Italy  City of Turin and province of Rome (divided into two
smaller units: city of Rome and outside of Rome
municipalities).
3 1,630,000
The  Netherlands Provinces responsible for matters of subnational or
regional importance (not health care).
12 1,380,000
Norway Hospital trusts responsible for providing specialist health
care in their geographical areas.
20 250,000
Scotland Health boards responsible for health care. Smallest boards 14 370,000
re. combined.
Sweden Counties responsible for providing health ca
patient level. Then a resource weight is attached to each
component. Resource weights are based on patient level
cost data from Sweden [17]. The ﬁrst cost component is
the procedure/treatment given during the hospital stay. For
instance, for AMI, treatment with coronary artery bypass
surgery (CABG) and percutaneous coronary intervention
(PCI) are registered and resource weights are attached to
them. Another component is the number of hospital days,
with a cost weight attached that describes the basic cost
of a hospital day. Inpatient stays for main diagnoses other
than AMI  are assessed by a cost per day corresponding to
the mean cost per day for all admissions registered in the
cost per patient database. All outpatient consultations are
registered and weighted by the mean cost of an outpatient
consultation. Eurostat purchasing power parities (PPP) for
hospital services [18] are used to convert costs to the cost
level in the EU15.
In the second approach, each country makes use of their
best available data to calculate hospital costs at the indi-
vidual patient level. Some countries may  take advantage of
cost data at the individual patient level, while others are
using classiﬁcation systems (e.g., DRGs) and related tariffs
as proxies of costs. Results of approach one and approach
two are supposed to supplement each other in the compar-
ative analyses of costs across countries. In both approaches,
the cost of pharmaceuticals dispensed outside hospitals
is recorded at pharmacy selling price as registered in the
national pharmaceutical databases. Then, the PPP for each
country’s Gross Domestic Product (GDP) is used to adjust
for cost level in each country.
3.3. Outcomes
In the EuroHOPE project outcome indicators are con-
sidered those measures of health that are attributable to
health care. The most important outcome measures are
mortality at the 30-day, 90-day and one-year follow up. In
addition, we use other outcome measures calculated from
registers such as readmission and complications, since it21 450,000
is generally agreed that these have an impact on patient
outcomes.
3.3.1. Regional comparison
We calculate indicators by countries and within
countries by regions. The regional indicators are based
on patients’ place of residence. Each country has deﬁned
the partition of its regions to be suitable for bench-
marking (Table 3). In Finland, Italy, Norway, Scotland and
Sweden the regions describe local authorities responsible
for health care, while in social health insurance countries
(the Netherlands and Hungary) the regions are based on
regional governmental or sub-national geographical divi-
sion where public authorities have no (Netherlands) or
limited responsibility of health care (Hungary). In the last
mentioned countries, the average population size of the
regions is much greater than in the Nordic countries and
Scotland. However, in all countries the metropolitan areas
are constructed so that they enable international compar-
ison.
3.4. Risk adjustment
When comparing countries, regions, hospitals, and
yearly patient cohorts, patient-associated factors must be
accounted for. EuroHOPE has endeavored to ensure mean-
ingful comparisons using three steps. Firstly, the disease
groups have been deﬁned so that they are as compara-
ble and homogeneous as possible. Secondly, information
on risk factors has been gathered from the patients’ medi-
cal history. Thirdly, statistical models have been applied to
adjust the indicators and calculated their 95% conﬁdence
intervals.
3.4.1. Risk adjustment variables
One of the most commonly-used, and clinically impor-tant, risk adjustment variable is comorbidity. Numerous
measures of comorbidity are available when using admin-
istrative data (for a review see e.g. [19–21], the most
common being the Elixhauser method [22] and the
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Table 4
Comorbid diseases in EuroHOPE AMI  study.
Comorbidity ICD-10 ICD-9 ATC/DDD
Hypertension I10*–I15* 40* C03*, C07* (with neither coronary artery
disease nor atrial ﬁbrillation indicates
hypertension), C08*, C09*
Coronary artery disease I20*–I25* 410*–414* N/A
Atrial ﬁbrillation I48* 4273* N/A
Cardiac insufﬁciency I50* 428* N/A
Diabetes mellitus E10*–E14* 250* A10A*, A10B*
Atherosclerosis I70* 440* N/A
Cancer C00*–C99**, D00*–D09* 140*–208* L01* (except L01BA01)
COPD and asthma J44*–J46* 4912*, 496*, 496* R03*
Dementia F00*–F03*, G30* 290*, 3310* N06D*
Depression F32*–F34* 2962*, 2963* N06A*
Parkinson’s disease G20* 332* N04B*
Mental disorders F20*–F31* 295*–298* except
2962* and 2963*
N05A* (except N05AB01 and N05AB04), and no
dementia
Renal  insufﬁciency N18* 585* N/A
Alcoholism F10*–F19* 291*, 304*, 305* N/A
430*–4
*
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aStroke I60*, I61*, I63*, I64*, G45* 
 Indicates that all subgroups are included i.e. I63* = I63.0–I63.9.
harlson Comorbidity Index (CMI) [23]). Besides comor-
idity chartings based on information about secondary
iagnoses in the hospital discharge data, the Anatomical
herapeutic Chemical (ATC) classiﬁcation system has been
sed to identify pharmaceutical treatments that are com-
on for a selection of relevant comorbid diseases [24–26].
sing the data available and experience of these measures,
s well as statistical testing, our disease-speciﬁc expert
roups separately tailored a set of conditions for each dis-
ase that were potentially used for risk adjustment. In the
nal risk adjustment only those conditions whose preva-
ence exceeded 1% in each of the participating countries’
ata for that particular disease were included.
Two different databases were used to identify for
omorbidity information in patients’ records: the hospital
ischarge register and the register of prescribed medicines.
he two sources overlap in terms of the content of informa-
ion, i.e. a person hospitalized with a speciﬁc comorbidity
as a high probability of having purchased a prescribed
edicine for that illness. On the other hand, the regis-
ers complement each other so that the information of the
omorbidities of patients becomes reliable. This is rele-
ant, in particular because of the expected undercoding of
econdary diagnoses in discharge registers. The diagnoses
main and secondary diagnoses separately) of patients’
npatient hospital treatments in the previous year (i.e. 365
ays before the index admission) are checked. The assump-
ion made is that if a person has been hospitalized with
 diagnosis of a comorbidity condition before the start of
he episode, the patient has had the comorbidity at the
ime of the event under observation (except among low
irth weight infants). Similarly, purchases for prescribed
edicines are checked for the last 365 days before the
tart of the episode of care (Fig. 1). Hospital discharges and
edicine purchases during the event or afterwards are not
hecked for comorbidities. In addition to checking the diag-
oses of a patient, we have counted the number of hospital
npatient days in the year preceding the index admission.
ge and sex of the patient are also considered in the risk
djustment.38* N/A
The comorbidities available for AMI  patients are pre-
sented in Table 4. For each indicator we  perform risk
adjustment with three different sets of confounders: (1)
age and sex (M1), (2) age, sex, hospital days in the previous
year, and comorbid diseases based on hospital discharge
data (M2), and (3) age, sex, hospital days in the previous
year, and comorbid diseases based on both medication and
hospital discharge data (M3). The comorbidities used in
each disease group vary; the table provides a broad per-
spective on the comorbidities selected in the study and in
the marking criteria.
3.4.2. Risk adjustment modeling
There are many possible methods that could be used
for risk adjustment, such as methods related both to
observable confounders (standardization using different
approaches, such as nonlinear regressions, propensity
score, conﬁdence intervals using shrinkage estimators and
other Bayesian methods) and unobservable confounders
(instrumental variable methods and two-stage methods)
[8]. In practice, the selection of appropriate methods is
based on balancing what can be done on a routine basis
with adequate methodological aspects. As the number
of indicators in EuroHOPE is high, the development of
reﬁned statistical models for each indicator separately is
not feasible when it comes to reporting and benchmarking
purposes.
Thus, we  chose to carry out an indirect standardization
for measures of incidence, while for all other indicators
a modeling strategy is adopted: logistic regression for
dichotomic responses (e.g. mortality), generalized linear
modeling for continuous responses (e.g. for costs logit-link
with gamma  distribution), and negative binomial modeling
for discrete responses (e.g. length of stay). The simpli-
ﬁed approach chosen is justiﬁed on the practical grounds
mentioned above. In addition, our methodology is more
accessible to a wider audience than are the more complex
alternatives, although we  recognize that more advanced
methods exist and that the reporting might beneﬁt from
those.
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In the estimation of the risk adjustment models a com-
plication arises from the involvement of many different
countries. Ideally, the individual-level data from all par-
ticipating countries would be pooled before estimating the
risk adjustment models However, not all countries have
permission to share the individual level data which is why
the risk adjustment is based on data from around half of
the included countries.
In each disease, the parameter estimates for the con-
founding factors are ﬁrst estimated for every process or
outcome measure using the broadest possible data for the
disease in question [e.g. for AMI  the international Euro-
HOPE comparison data, available from the year 2007 from
Finland, Hungary, Sweden, Norway (data of 2009) and two
regions of Italy]. The estimations are made by weighting the
data so that each country has the same weight. Then, the
coefﬁcients of each model are made available to all part-
ners who then calculate individual-level-predicted values
for the indicators. The predicted values are then summed
up to country and regional level. The ratio of the observed
value and the expected value of the dependent variable in
the comparable unit can be multiplied with the average
value of the indicator in the pooled data to constitute the
risk adjusted indicator.
3.4.3. Standardization in data processing and
calculations
From a practical point of view, the whole process of
risk adjustment and reporting of the indicators has been
automatized as much as possible. Each partner was individ-
ually responsible for producing its own national EuroHOPE
comparison data, with the principles stated in the disease-
speciﬁc study protocols.6 After this, the partners executed
a ﬁxed ﬁle in a common statistical program (Stata) which
automatically processed the data, found the coefﬁcients for
the models from the EuroHOPE server, and calculated the
predicted values and the risk adjusted values at all levels.
6 The study protocols for each disease are available at
http://www.eurohope.info.usted and risk-adjusted shares and their 95% conﬁdence intervals.
Finally, the descriptive statistics along with the country-,
regional- and hospital-level indicators and their conﬁdence
intervals were automatically transferred to a reporting
template.
In addition to all this, the common statistical pro-
grams also included material (for example, modeling with
the country-speciﬁc data, graphing etc.) which produced
additional material for the study. The automatization
of the indicator production minimized the chances for
human programming errors, but most importantly it saved
time and resources of all partners. Also, this enabled the
use of individual-level data to the fullest extent in all
countries.
4. Illustrative examples
The results of analyses for AMI  patients are used to illus-
trate the methods for risk adjustment. In Fig. 3, the three
alternative risk adjustment approaches (M1, M2  and M3)
for the one-year mortality are compared with crude mor-
tality between the Swedish regions (counties). It seems
that the different risk adjustment methods generate sim-
ilar county rankings: The correlation coefﬁcient between
the risk adjusted measures varied from 0.99 to 0.96. The
crude mortality was less clearly associated with the risk
adjusted ﬁgures (correlations 0.90–0.80).
Fig. 4 describes regional variation in age- and sex-
standardized one-year mortality of AMI  patients in the
seven countries. Mortality as well as its regional variation
was much higher in Finland, Hungary and Scotland than in
the three other countries.
5. Discussion
The disease-based approach is attractive for interna-
tional comparative performance comparison, because it
produces various measures not only at country level but
also at regional and hospital level across countries. Its use-
fulness depends, nevertheless, on comprehensive register
data being available and the possibility of linking the hos-
pital discharge register to other databases. The EuroHOPE
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roject is one of the ﬁrst international projects to discover
he possibilities of the approach at this scale, aiming to
ink the data-sources using entirely standardized proce-
ures across countries. The beneﬁts are already apparent
rom the preliminary results, which indicate clearly that
he approach gives new possibilities for performance com-
arison of certain patient groups. A variety of indicators
ould be used for benchmarking and data were provided at
arious relevant levels, that is, at the levels where most
f the actions in policy making are taken. Comparison
ith other national and international quality databases –
uch as those of the OECD Health Care Quality Indicator
roject (HCQI) and the Agency for Healthcare Resources
nd Quality (AHRQ) – reveals that the EuroHOPE project
as grasped subtle and richer information on the selected
iseases including both long-term outcomes and costs. In
ddition, the follow-up of patients extends through the
hole clinical pathway.
There are still challenges to be met. For some of those
articipating countries, the formal and technical processes
f having access to data are too slow and cumbersome. In
hese countries, public authorities need to be reminded by
esearchers that domestic and international comparisons
equire access to detailed patient-level data. As highlighted
y the Hospital Data Project [27] there are differences in
oding practices across countries and the quality of data
s not always comparable. For example, the incidence of
MI  (new AMI patients/population) was clearly higher in
weden and Norway compared to Finland and Hungary.
t this stage, it is not clear whether this reﬂects true dif-
erences in the use of acute hospital care of the patient
roup or coding differences of the main diagnosis. Another
otential bias is related to the fact that patients are iden-
iﬁed from the hospital discharge register. Some patients
ay  die (or recover) before they are diagnosed in a hos-
ital. If the proportion of these patients varies between
ountries, there is a potential bias in the outcome and
ncidence comparison. In addition, organizational structure
s well as the availability of linkable data on long-termry, adjusted for age and sex, with conﬁdence intervals.
and rehabilitation care varies between countries. How-
ever, since we are utilizing individual-level data we can
perform a sensitivity analysis to validate our main ﬁnd-
ings. For example, we can calculate the length of stay as
well as cost both including and excluding rehabilitation
and long term care. In addition, the merged international
EuroHOPE comparison data enables us to use more sophis-
ticated methods (such as propensity score matching) to
increase the comparability of performance measurement
[28].
The EuroHOPE project utilized mainly available reg-
ister data in which outcome can be evaluated using
various mortality measures or intermediate indicators
such as complications, readmissions etc. These measures
are crude and do not cover all dimensions of outcomes
such as the effects of care on quality of life or func-
tional status. For these measures patients are the only
valid source of information. Gathering data directly from
patients includes considerable expenses and feasibility
challenges. Thus, the pilot studies for stroke and breast
cancer patients evaluate the feasibility of establishing
international comparisons on measuring health related
quality of life and patient satisfaction in demanding patient
environment.
The EuroHOPE project is based on data gathered from
seven countries. The aim of the project is to develop
methods for performance assessment that can be used for
routine evaluation. Documentation with the publicly avail-
able study protocols, programming and reporting material
make entry into the EuroHOPE group potentially easy.
New countries must ﬁrst develop and adjust their infor-
mation systems while laws that might hinder available
data linkages may  need to be addressed. For example,
an electronic record system (including all health care
activities) is under development in many countries and
will give new, path-breaking possibilities for the devel-
opment of the disease-based approach. This requires that
data using standardized and internationally compara-
ble deﬁnitions of activities and classiﬁcations describing
lth Polic
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the treatments (i.e. diagnosis, procedures) are nation-
ally available for research and thus enable evaluation of
the performance across countries, regions and produc-
ers.
Acknowledgements
This project was undertaken within the European Union
7th Framework Programme European Health Care Out-
comes, Performance and Efﬁciency (EuroHOPE), Contract
no. 241721
References
[1] Häkkinen U, Joumard I. Cross-country analysis of efﬁciency in OECD
health care sector: options for research. OECD, Economics Depart-
ment Working Papers, No. 554; 2007.
[2]  Häkkinen U. The PERFECT-project: measuring performance of health
care episodes. Annals of Medicine 2011;43(Suppl. 1):S1–3.
[3] Smith PC, Häkkinen U. Information strategies for decentralization. In:
Saltman R, Bankauskaite V, Vrangbaeck K, editors. Decentralization
in  health care. Berkshire: Open University Press; 2007. p. 206–24.
[4] Street A, Häkkinen U. Health system productivity and efﬁciency. In:
Smith PC, Mossialos E, Papanicolas I, Leatherman S, editors. Perfor-
mance measurement for health system improvement. Experiences,
challenges and prospects. Cambridge: Cambridge University Press;
2009. p. 222–48.
[5] Busse R. Do diagnosis-related groups explain variations in hospital
cost and length of stay? Analyses from the EuroDRG project for 10
episodes of care across 10 European countries. Health Economics
2012;21(Suppl. 2):1–5.
[6] Wray NP, Ashton CM,  Kuykendall DH, Hollingsworth JC. Using
administrative databases to evaluate the quality of medical care: a
conceptual framework. Social Science & Medicine 1995;40:1707–15.
[7] de Pouvourville G, Minvielle É. Measuring the quality of hospital care:
the state of the art. What information should be made available to the
public? In: Measuring up: improving health system performance in
OECD countries. Paris: Organisation for Economic Co-operation and
Development; 2002. p. 251–75.
[8] Iezzoni LI, editor. Risk adjustment for measuring health care out-
comes. Chicago: Health Administration Press; 2003.
[9] Terris DD, Aron DC. Attribution and causality in health-care per-
formance measurement. In: Smith PC, Mossialos E, Papanicolas I,
Leatherman S, editors. Performance measurement for health system
improvement: experiences, challenges, and prospects. Cambridge:
Cambridge University Press; 2009. p. 311–38.
10] Sund R. Utilisation of administrative registers using scientiﬁc knowl-
edge discovery. Intelligent Data Analysis 2003;7:501–19.
11] Heijink R, Koopmanschap MA,  Polder JJ. International comparison of
cost of illness. RIVM reports; 2006.
[y 112 (2013) 100– 109 109
12] Solon JA, Feeney JJ, Jones SH, Rigg RD, Sheps CG. Delineating episodes
of  medical care. American Journal of Public Health 1967;57:401–8.
13] Hornbrook M,  Hurtado A, Johnson R. Health care episodes: deﬁnition,
measurement and use. Medical Care Review 1985;42:163–218.
14] Rosen AK, Mayer-Oakes A. Episodes of care: theoretical frameworks
versus current operational realities. The Joint Commission Journal on
Quality Improvement 1999;25:111–28.
15] Kobel C, Thuilliez J, Bellanger M,  Preiffer K. DRG systems and sim-
ilar patient classiﬁcation systems in Europe. In: Busse R, Quentin
W,  Wiley M,  editors. Diagnosis-related groups in Europe. Moving
towards transparency, efﬁciency and quality in hospitals. Berkshire,
UK: Open University Press; 2011. p. 37–58.
16] Geue C, Lewsey J, Lorgelly P, Govan L, Hart C, Briggs A. Spoilt for
choice: implications of using alternative methods of costing hospital
episode statistics. Health Economics 2012;21:1201–16.
17] Cost per patient (KKP – Kostnad per patient) project. See
http://www.skl.se/kpp
18] Eurostat, OECD. Methodological manual on purchasing power pari-
ties.  Luxembourg: European Communities. OECD; 2006.
19] de Groot V, Beckerman H, Lankhorst GJ, Bouter LM.  How to measure
comorbidity: a critical review of available methods. Journal of Clinical
Epidemiology 2003;56:221–9.
20] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J, et al.
Coding algorithms for deﬁning comorbidities in ICD-9-CM and ICD-
10 administrative data. Medical Care 2005;43:1130.
21] Holman C, Preen D, Baynham N, Inn J, Semmens J. A multipurpose
comorbidity scoring system performed better than the Charlson
index. Journal of Clinical Epidemiology 2005;58:1006–14.
22] Elixhauser A, Steiner C, Harris R, Coffey R. Comorbidity measures for
use with administrative data. Medical Care 1998;36:8–27.
23] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of clas-
sifying prognostic comorbidity in longitudinal studies: development
and validation. Journal of Chronic Diseases 1987;40:373–83.
24] Maio V, Yuen E, Rabinowitz C, Louis D, Jimbo M,  Donatini A, et al.
Using pharmacy data to identify those with chronic conditions in
Emilia Romagna, Italy. Journal of Health Services Research & Policy
2005;10:232–8.
25] Lamers L, van Vliet R. The pharmacy-based cost group model: val-
idating and adjusting the classiﬁcation of medications for chronic
conditions to the Dutch situation. Health Policy 2004;68:113–21.
26] Naughton C, Bennett K, Feely J. Prevalence of chronic disease in the
elderly based on a national pharmacy claims database. Age and Age-
ing  2006;35:633–6.
27] Hospital Data Project. Phase 2. Final report; 2008.
28] Schreyögg J, Stargardt T, Tiemann O. Costs and quality of hospitals in
different health care systems: a multilevel approach with propensity
score matching. Health Economics 2011;20:85–100.
29] Medin E, Häkkinen U, Linna M,  Anthun KS, Kittelsencomparison: nordic experience. Health Policy 2013,
http://dx.doi.org/10.1016/j.healthpol.2013.02.004.
30] Eurostat. Handbook on price and volume measures in national
account. Luxemburg: European Communities; 2001.
